Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Overview
CoChat Summary
TL;DR
An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.
Key findings
- For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
- For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
- TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
- In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).
Methods
- Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
- Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
- Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.
Limitations
- The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
- The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
- Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
In type 1 diabetes, the Results (Table 2; page unavailable) show weaker correlations for hypoglycemia and glycemic variability than for mean glucose at 15 days. But they also show that both correlations increase as sampling extends from 3 to 15 days, contrary to the citing sentence’s claim that an increase with longer sampling has not been shown. The paper does not frame this analysis as >70% CGM use over 14 days. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that correlations with the full three-month data increased as sampling lengthened for both hypoglycemia and glycemic variability. From 3 to 15 days, r² rose from 0.32 to 0.66 for values ≤70 mg/dL and from 0.36 to 0.70 for coefficient of variation—the opposite of the attributed claim. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The first longitudinal CGM data demonstrated a 13percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61).”
What the sources say
- Disputedcites [61] 62. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med. 2016;375(7):644-654. sourceExperimental — accuracy not yet measured
The Study Outcomes report different CGM time-in-range results: 59.5% to 74.7% overnight and 56.8% to 66.3% over 24 hours with closed-loop therapy. The paper defines its target range as 63–140 mg/dL, not 70–140 mg/dL; it does not report the claimed increase from 43% to 56%. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Partly supportedcites [2] 2. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 2017;40(4):538-545. sourceExperimental — accuracy not yet measured
The Introduction reports that several randomized trials found CGM benefits, including reduced HbA1c and hypoglycemia, particularly in adults with type 1 diabetes. But the Conclusions say this trial included only insulin-pump users; extending its results to people using injections is described as reasonable, not demonstrated. The paper therefore does not establish benefits regardless of insulin delivery method or across all people with diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Not checked — no full text of the sourcecites [5] 5. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, for the DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017; 40:736-741. source
- Supportedcites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. source
The Discussion reports significant glycemic benefits from real-time CGM that were comparable with pump (CSII) and injection (MDI) therapy. The study concerns people with type 1 diabetes. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [7] 7. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, openlabel, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893-902. source
- Not checked — no full text of the sourcecites [8] 8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263. source
- Partly supportedcites [9] 9. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulintreated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. sourceExperimental — accuracy not yet measured
The Results report significant reductions in hypoglycemic events with flash glucose monitoring in adults with insulin-treated type 2 diabetes, supporting a clinical benefit. The Results also state that 95% of participants used an insulin pen or syringe and 5% used continuous subcutaneous insulin infusion; the paper does not establish that the benefit held regardless of insulin delivery method. No page numbers are available in our copy. (LLM, conf=0.85)
- Partly supportedcites [10] 10. Choudhary P, Olsen BS, Conget I, et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18(5):288-291. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the CGM-based MiniMed 640G pump system can help patients with type 1 diabetes avoid hypoglycemia. But this short, uncontrolled study examined a predictive pump-suspension system, not CGM use regardless of insulin delivery method; it does not establish a benefit across delivery methods or isolate the benefit of CGM itself. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Could not verifycites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. sourceExperimental — accuracy not yet measured
The Prespecified outcomes section (page unavailable) identifies HbA1c as this type 1 diabetes study’s primary endpoint. Neither that section nor the Discussion passages establish that A1C is the key surrogate marker for long-term complications in people with both type 1 and type 2 diabetes. Searches for that surrogate-marker relationship and for complications found no passage stating it. (LLM, conf=0.72)
- Partly supportedcites [33] 32. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55(12):3155-3162. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links near-normal glycaemia with reduced complication risk in type 1 diabetes, and Methods > Outcome measure (page unavailable) uses HbA1c as this trial’s primary endpoint. The paper does not establish HbA1c as the key surrogate marker for long-term complications in both type 1 and type 2 diabetes. (LLM, conf=0.81)
- Could not verifycites [32] 31. Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. Diabetes Care 2017;40:655 ʹ 662. sourceExperimental — accuracy not yet measured
The Baseline Assessment section says HbA1c was measured at the start of monitoring, but does not describe it as a surrogate marker for long-term complications. The Research Design and Methods section examines arrhythmias during hypoglycemia, not A1C as a primary endpoint in CGM studies. Searches for the surrogate-marker and primary-endpoint claims found no supporting passage in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 16 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the advent of newer studies of CGM in noninsulin‐treated individuals and increasing uptake, the utility of CGM is progressively being endorsed in this population.”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycaemia is associated with an increased risk of vascular events, explaining recent consensus advocating hypoglycaemic exposure at <1% (i.e.<15 min/day) in individuals at high CV risk.137,138”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering the older age of participants and comorbid conditions reported, the mean HbA1c, GMI, TIR, and TBR results (8.0%, 7.6%, 56%, and 1.0% at 6 months, respectively) demonstrate close adherence to established glycemic targets (23, 24, 38).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [193]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ FIGURES / TABLES · p. 4
“2 Figures / 3 Tables”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Time in Ranges · p. 11
“Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Cited by
Items 901–1,000 of 3,959
Smaniotto, V., Heller, S. R., O'Neal, D. N., JENDLE, J. H., Cukierman‐Yaffe, T., Arrieta, A., Thijs, I., Castañeda, J., van den Heuvel, T. R. A., & Cohen, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16227 · Cited by 22
Self-citationTime in range—A new gold standard in type 2 diabetes research?
Goshrani, A., Lin, R., O'Neal, D. N., & Ekinci, E. I. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16279 · Cited by 26
Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis
de Boer, I. H., Anderson, L. D., Ashford, N. K., Ayers, E., Bansal, N., Hall, Y. N., Hirsch, I. B., Hoofnagle, A. N., Hsu, S., Jones, E., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000693 · Cited by 21
Self-citationWyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf116 · Cited by 31
“In fact, the International Consensus on Time in Range noted in their recommendation that “Recent data suggest that even more stringent targets and greater attention to overnight glucose profiles may be required…” 217 .”
InfluentialPolsky, S., Garcetti, R., Pyle, L. L., Joshee, P., Demmitt, J. K., & Snell‐Bergeon, J. K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230476 · Cited by 18
White coat adherence effect on glucose control in adult individuals with diabetes
Züger, T., Gloor, M., Lehmann, V. F., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108392 · Cited by 18
The challenge of diabetes home control in COVID-19 times: Proof is in the pudding
Cotovad, L., Pérez, C. T., Tenreiro, A. M. P., Sánchez-Bao, A., & Bellido, D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108379 · Cited by 19
“[9] Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al.”
Real-world outcomes with different technology modalities in type 1 diabetes
Beato-Víbora, P. I., Gallego-Gamero, F., & Ambrojo-López, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.02.028 · Cited by 18
Dimosthenopoulos, C., Liatis, S., Kourpas, E., Athanasopoulou, E., Driva, S., Makrilakis, K., & Kokkinos, A. D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14390 · Cited by 22
Shapira, A., Volkening, L. K., Borus, J. S., & Laffel, L. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035451 · Cited by 19
“198 Journal of Diabetes Science and Technology 17(1)”
BackgroundInfluentialSelf-citationRiveline, J., Vergès, B. L., Detournay, B., Picard, S., Benhamou, P., Bismuth, É., Bordier, L., Jeandidier, N., Joubert, M., Roussel, R., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101306 · Cited by 20
Patel, R., Crabtree, T. S. J., Taylor, N., Langeland, L., Gazis, A., Mendis, B., Wilmot, E. G., & IDRIS, I. R. (2022) · Diabetic Medicine · doi:10.1111/dme.14793 · Cited by 23
Passanisi, S., Salzano, G., Galletta, F., Aramnejad, S., Caminiti, L., Pajno, G. B., & Lombardo, F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.846137 · Cited by 19
“time within range, time below range, time above range, and coefficient of variation) are currently recognized as appropriate and useful clinical targets that complement HbA1c in the evaluation of glycemic control (40).”
BackgroundSmith, K., Taylor, G., Brunsgaard, L. H., Walker, M., Davies, K. A. B., Stevenson, E., & West, D. J. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002820 · Cited by 26
Magkos, F., Reeds, D. N., & Mittendorfer, B. (2022) · Physiological Reviews · doi:10.1152/physrev.00015.2022 · Cited by 21
Lachin, J. M., Bebu, I., Gao, X., Nathan, D. M., & Zinman, B. (2022) · Diabetes Care · doi:10.2337/dc21-2298 · Cited by 19
Chien, A., THANASEKARAN, S., Gaetano, A., IM, G. H., Wherry, K., MacLeod, J., & Vigersky, R. A. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.22283 · Cited by 20
Mohan, V., Joshi, S., Mithal, A., Kesavadev, J., Unnikrishnan, A., Saboo, B., Kumar, P. R. G., Chawla, M. S., Bhograj, A., & KOVIL, R. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01355-4 · Cited by 31
“In these cases, both TIR and SMBG tools need to be used for best decision-making practices.”
BackgroundInfluentialSelf-citationCho, S., Aiello, E. M., Özaslan, B., Riddell, M. C., Calhoun, P. M., Gal, R. L., & Doyle, F. J. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231153896 · Cited by 21
Self-citationDodesini, A. R., Borella, N. D., Lepore, G., Bonfadini, S., Corsi, A. M., Scaranna, C., Bellante, R., & Trevisan, R. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0031 · Cited by 18
Castañeda, J., Arrieta, A., van den Heuvel, T. R. A., & Cohen, O. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15139 · Cited by 21
Reutrakul, S., Irsheed, G. A., Park, M., Steffen, A. D., Burke, L., Pratuangtham, S., Baron, K. G., Duffecy, J. L., Perez, R. I., Quinn, L., et al. (2023) · Sleep Health · doi:10.1016/j.sleh.2023.07.007 · Cited by 23
Patient Perspectives on the Benefits and Challenges of Diabetes and Digital Technology
Edelman, S. V., Cheatham, W. W., Norton, A., & Close, K. L. (2023) · Clinical Diabetes · doi:10.2337/cd23-0003 · Cited by 21
“Those of most value are single-page reports that can be reviewed, fi led, and shared as a decision-making tool (36).”
BackgroundSelf-citationMarch, C. A., Sherman, J., Bannuru, R. R., Fischer, A., Gabbay, R. A., Rodriguez, H., Rodriguez, J., Weissberg-Benchell, J. A., Woodward, C., & ElSayed, N. A. (2023) · Diabetes Care · doi:10.2337/dci23-0083 · Cited by 21
The emerging role of digital health in the management of asthma
Kaplan, A. G., Boivin, M. R., Bouchard, J., Kim, J., Hayes, S. W., & Licskai, C. J. (2023) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223231209329 · Cited by 27
Food & You: A digital cohort on personalized nutrition
Héritier, H., Allémann, C., Balakiriev, O., Boulanger, V., Carroll, S. F., Froidevaux, N., Hugon, G., Jaquet, Y., Kebaili, D., Riccardi, S., et al. (2023) · PLOS Digital Health · doi:10.1371/journal.pdig.0000389 · Cited by 22
Lablanche, S., Delagenière, J., Jalbert, M., Sonnet, E., Bénichou, M., Arnold, N., Spiteri, A., Berre, J. P. L., Renard, É., Chevalier, N., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0414 · Cited by 22
Use of Diabetes Technologies and Retinopathy in Adults With Type 1 Diabetes
Liu, T. Y. A., Shpigel, J., Khan, F., Smith, K. E., Prichett, L. M., Channa, R., Kanbour, S., Jones, M., Abusamaan, M. S., Sidhaye, A. R., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0728 · Cited by 25
Wang, Y., Li, S., Lu, J., Feng, K., Huang, X., Hu, F., Sun, M., Zou, Y., Li, Y., Huang, W., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06136-1 · Cited by 23
“Of the numerous metrics generated from CGM, TIRs have been recommended by international consensus statements and guidelines as important measures of glucose control [16, 17, 19].”
Continuous Glucose Monitoring for Management of Type 2 Diabetes and Perinatal Outcomes
Padgett, C. E., Ye, Y., Champion, M. L., Fleenor, R. E., Orfanakos, V. B., Casey, B. M., & Battarbee, A. N. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005609 · Cited by 23
Angellotti, E., Muppavarapu, S., Siegel, R. D., & Pittas, A. G. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0405 · Cited by 21
Scott, S. N., Christiansen, M. P., Fontana, F. Y., Stettler, C., Bracken, R. M., HAYES, C. A., Fisher, M., Bode, B. W., LAGROU, P. H., Southerland, P., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2302 · Cited by 18
Thyde, D. N., Mohebbi, A., Bengtsson, H. L., Jensen, M. L., & Mørup, M. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820912411 · Cited by 26
McCarthy, O. M., Eckstein, M. L., Scott, S. N., Fontana, F. Y., Christiansen, M. P., Stettler, C., Fisher, M., Bode, B. W., Riddell, M. C., HAYES, C. A., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001245 · Cited by 20
LDL-Cholesterol versus Glucose in Microvascular and Macrovascular Disease
Emanuelsson, F., & Benn, M. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa242 · Cited by 19
Automated Insulin Delivery: Easy Enough to Use in Primary Care?
HEILE, M. K., Hollstegge, B., Broxterman, L., Cai, A., & Close, K. L. (2020) · Clinical Diabetes · doi:10.2337/cd20-0050 · Cited by 19
“Generally, TIR is considered the percentage of time a person’s glucose remains between 70 and 180 mg/dL (12).”
BackgroundSelf-citationMcAuley, S. A., Vogrin, S., Lee, M. H., Paldus, B., Trawley, S. L., de Bock, M. I., Abraham, M. B., Bach, L. A., Burt, M. G., Cohen, N. D., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0589 · Cited by 22
Roversi, C., Vettoretti, M., Favero, S. D., Facchinetti, A., Choudhary, P., & Sparacino, G. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211012392 · Cited by 19
Felix dies natalis, insulin… ceterum autem censeo “beta is better”
Piemonti, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01737-3 · Cited by 19
Riso, D. D., Bertini, S., Spaggiari, S., Olivieri, F., Zaffani, S., Comerlati, L., Marigliano, M., Piona, C. A., & Maffeis, C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18115549 · Cited by 23
“Several glucose metrics were derived from the AGP analysis: percentage of time below the range (<70 mg/dL) (%TBR), percentage of time in the target range (70–180 mg/dL) (%TIR), percentage of time above the range (>180 mg/dL) (%TAR), standard deviation of the mean glucose, coefficient of variation (%CV), and Glucose Ma…”
MethodInfluentialThe Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes
Inoue, R., Nishiyama, K., Li, J., Miyashita, D., Ono, M., Terauchi, Y., & Shirakawa, J. (2021) · Cells · doi:10.3390/cells10071589 · Cited by 23
“The concept of time in range (TIR) has been proposed as a target range for glycaemic control, and the recommended range for general adults with T1D or T2D is a blood glucose level within 70–180 mg/dL for at least 70% of the day [50].”
BackgroundLombardo, F., Salzano, G., Bombaci, B., Basile, P., Lucania, G., Alibrandi, A., & Passanisi, S. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108988 · Cited by 24
William, J., McCluskey, J. T., & Gleeson, N. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.324 · Cited by 21
“(4) Outcomes required in studies as per our inclusion criteria amended to include at least 1 outcome.”
BackgroundClosed-Loop Artificial Pancreas Therapy for Type 1 Diabetes
Zhou, K., & Isaacs, D. M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01733-1 · Cited by 20
Urakami, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030781 · Cited by 19
“9–10 mmol/L) [66] with a marked decrease of TBR compared with isCGM in children with type 1 diabetes (TBR: 4.”
BackgroundMethodSelf-citationInsulin Pump Therapy and Continuous Glucose Monitoring
Schütz-Fuhrmann, I., Rami-Merhar, B. M., Fröhlich-Reiterer, E. E., Hofer, S. E., Tauschmann, M., Mader, J. K., Resl, M., Kautzky‐Willer, A., Winhofer-Stöckl, Y., Laimer, M., et al. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780199568604.001.0001 · Cited by 19
The dawn phenomenon across the glycemic continuum: Implications for defining dysglycemia
Li, C., Ma, X., Yin, J., Mo, Y., Zhang, L., Lu, J., Lu, W., Bao, Y., Vigersky, R. A., Zhou, J., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108308 · Cited by 19
Self-citationMiya, A., Nakamura, A., Handa, T., Nomoto, H., Kameda, H., Cho, K. Y., Nagai, S., Miyoshi, H., & Atsumi, T. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13426 · Cited by 19
Rebound Hypoglycemia and Hyperglycemia in Type 1 Diabetes
Hansen, K. W., & Bibby, B. M. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231168379 · Cited by 17
Eliasson, B., Kjölhede, E. A., Salö, S., Nielsen, N. F., & Eeg‐Olofsson, K. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01572-z · Cited by 21
“In 2019, an international consensus report provided standardized CGM‑ derived measurements for clinical care, as well as target levels for different patient groups [2].”
BackgroundBattarbee, A. N., Durnwald, C. P., Yee, L. M., & Valent, A. M. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005669 · Cited by 21
“25 Currently, this can be done by accessing the settings from the mobile application or website for some CGM devices.”
Cock, D. D., Schreurs, L., Steenackers, N., Pazmiño, S., Cools, W., Eykerman, L., Thiels, H., Mathieu, C., & der Schueren, B. V. (2024) · Diabetic Medicine · doi:10.1111/dme.15415 · Cited by 23
“4 Additionally, a recent study also demonstrated an elevation in TIR during the 24 h following exercise when compared to days without exercise.”
Self-citationMazzotta, F. A., Paoli, L. L., Rizzi, A., Tartaglione, L., Leo, M. L., Popolla, V., Barberio, A., Viti, L., Leo, M. A. S. D., Pontecorvi, A., et al. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00319-w · Cited by 31
“The development of CGM systems allows physicians to utilize new parameters which provide useful information regarding intra-and inter-day glucose variations [4].”
MethodBasiri, R., & Cheskin, L. J. (2024) · Nutrients · doi:10.3390/nu16234005 · Cited by 26
“In our first model, we used recommendations for blood glucose control for patients with diabetes from the American Diabetes Association [36]; therefore, blood glucose concentrations above 250 mg/dL were defined as the very high range, 180 to 250 mg/dL as high, and 70 to 180 mg/dL as TIR.”
Okuno, T., Macwan, S. A., Norman, G. J., Miller, D. R., Reaven, P. D., & Zhou, J. J. (2025) · Diabetes Care · doi:10.2337/dc25-0716 · Cited by 23
Molfetta, S. D., Gioia, L. D., Caruso, I., Caporusso, M., Trerotoli, P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70150 · Cited by 24
“54,55 Additionally, as compared with Aiello et al., our meta-analysis also included studies published in the years 2021 – 2025, comprising two RCTs evaluating iLet BP and two RCTs evaluating Omnipod 5.”
Pleus, S., Eichenlaub, M., Dabla, P. K., Diem, P., Boija, E. E., Fokkert, M. J., Hinzmann, R., JENDLE, J. H., Klonoff, D. C., Lu, J., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120728 · Cited by 26
Linder, T., Dressler‐Steinbach, I., Wegener, S., Schellong, K., Schmidt, S., Eppel, D., Monod, C., Heinzl, F., Redling, K., Winzeler, B. F., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00288-8 · Cited by 30
Dhatariya, K., Bergenstal, R. M., Al‐Sofiani, M. E., Albanese-O’Neill, A., Battelino, T., Close, K. L., Block, C. E. M. D., Dutta, S., Galindo, R. J., GhavamiNejad, A., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00331-6 · Cited by 33
Self-citationMcGill, J. B., Weiß, D., GRANT, M. L., Jones, M. C., Kendall, D. M., & Hoogwerf, B. J. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13099 · Cited by 22
“This observation is supported by the study of Akturk et al in which additional doses of TI given to patients with T1DM 60 and/or 120 minutes after a meal reduced postprandial glucose excursions and improved glucose time in range with lesser time in hypoglycemia.(15) With growing adoption of continuing glucose monitori…”
BackgroundResultElhadd, T. A., Bashir, M., Baager, K. A., Ali, H. A., Al-Mohannadi, D., Dabbous, Z., Malik, R. A., & Abou-Samra, A.-B. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108589 · Cited by 17
Homer, A. R., Taylor, F., Dempsey, P. C., Wheeler, M. J., Sethi, P., Grace, M. S., GREEN, D. J., Cohen, N. D., Larsen, R. N., Kingwell, B. A., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.07.001 · Cited by 23
A New Analysis Tool for Continuous Glucose Monitor Data
OLAWSKY, E. A., Zhang, Y., Eberly, L. E., Helgeson, E. S., & Chow, L. S. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211028909 · Cited by 19
Divani, M., Georgianos, P. I., Didangelos, T., Liakopoulos, V., Makedou, K., Iliadis, F. S., Savopoulos, C. G., & Grekas, D. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184116 · Cited by 20
“A unique advantage of CGM is that this technique facilitates the assessment of shortterm glucose variability and identification of asymptomatic hypoglycemia [8,11].”
BackgroundMethodType 1 Diabetes in Pregnancy: A Review of Complications and Management
Huda, M. S. B., Jaffar, F., & Laycock, K. (2021) · Current Diabetes Reviews · doi:10.2174/1573399818666211105124829 · Cited by 25
Barua, S., Sabharwal, A., GLANTZ, N. M., Conneely, C., LAREZ, A. J., Bevier, W. C., & Kerr, D. E. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101241 · Cited by 21
Sherrill, C. H., Lee, S., & Bradley, C. L. (2021) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2021.11.021 · Cited by 20
Cichosz, S. L., Jensen, M. H., & Hejlesen, O. K. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211069177 · Cited by 20
Fathi, A. E., Fabris, C., & Breton, M. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.795895 · Cited by 19
“3 Outcome Metrics Algorithm performance was assessed using established metrics of glycemic variability and quality of glycemic control (40), including, time in the target range of 70-180 mg/dL (TIR); time in hypoglycemia <70 mg/dL (TBR); and time in hyperglycemia >180 mg/dL (TAR) (A complete list of outcome metrics ar…”
MethodModzelewski, K. L., Murati, J., Charoenngam, N., Rehm, C., & Steenkamp, D. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0557 · Cited by 19
Eckstein, M. L., Brockfeld, A., Haupt, S., Schierbauer, J., Zimmer, R. T., Wachsmuth, N. B., Zunner, B. E. M., Zimmermann, P., Erlmann, M. P., Obermayer-Pietsch, B. M., et al. (2022) · Biology · doi:10.3390/biology11020338 · Cited by 21
“In T1DM and T2DM, low glucose levels begin with values below 70 mg/dL and turns into clinical relevant hypoglycemia once below 54 mg/dL according to recent guidelines [14].”
BackgroundMethodMao, Y., Tan, X. Q., Seng, A., Wong, P., Toh, S.-A. E. S., & Cook, A. R. (2022) · Health Data Science · doi:10.34133/2022/9892340 · Cited by 22
“Other than blood glucose variability, recent studies recommended clinical targets including the average and time in range [11], while the mean amplitude of glycemic excursions [12] quantifies glucose stability.”
BackgroundMethodLing, J., Ng, J. K., Lau, E. S. H., Ronald, C. W., Kong, A. P. S., Luk, A. O. Y., Kwok, J. S.-S., Szeto, C., Chan, J. C. N., & Chow, E. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.03.029 · Cited by 20
“uACR (mg/mmol) 100 (28-305) 26 (5-105) 163 (41-271) 353 (125-423) 0.”
Matabuena, M., Félix, P., Meijide-Garcia, C., & Gudé, F. (2022) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2022.106905 · Cited by 24
Kim, D. K., Ko, G. J., Choi, Y., Jeong, K. H., Moon, J.-Y., Lee, S. H., & Hwang, H. S. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110016 · Cited by 20
Munda, A., Kovacic, C., & Barlovič, D. P. (2022) · Metabolites · doi:10.3390/metabo12111137 · Cited by 19
Oriot, P., & Hermans, M. P. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108385 · Cited by 21
McCarthy, O. M., Christensen, M. B., Kristensen, K. B., Schmidt, S., Ranjan, A. G., Bain, S. C., Bracken, R. M., & Nørgaard, K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0542 · Cited by 18
Self-citationSmith, G. J., Abraham, M. B., de Bock, M. I., Fairchild, J. M., King, B., Ambler, G. R., Cameron, F. J., McAuley, S. A., KEECH, A. C., Jenkins, A. J., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0101 · Cited by 17
“…recommendations on characterizing time in range state valid CGM readings should be available for at least 70% over the 14-day sampling period, 13 to date there has been relatively little exploration as to the impact of missing data on the accuracy of metrics of glycemia derived from CGM…”
BISKUPIAK, J. E., Ramos, M., Levy, C. J., Forlenza, G. P., Hopley, C. D. J., Boyd, J., Swift, D., Lamotte, M., & Brixner, D. I. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.22331 · Cited by 26
Gavin, J. R., & Bailey, C. J. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0057 · Cited by 18
Kusinski, L. C., Brown, J., Hughes, D. J., & Meek, C. L. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292094 · Cited by 21
“Firstly, CGM metrics in common use [12] may be just as PLOS ONE Acceptability of continuous glucose monitoring”
MethodBergenstal, R. M. (2023) · Diabetes Spectrum · doi:10.2337/dsi23-0005 · Cited by 20
Self-citationXu, Y., Dunn, T. C., Bergenstal, R. M., Cheng, A., Dabiri, Y., & Ajjan, R. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0564 · Cited by 21
“Since the more widespread use of CGM for diabetes management, there has been an increase in clinically relevant glycemic parameters 4 with relatively little exploration of how these glucose measures interact.”
Self-citationBraem, C. I. R., Yavuz, U. Ş., Hermens, H. J., & Veltink, P. H. (2024) · Sensors · doi:10.3390/s24051526 · Cited by 24
“Monitoring time can be multiple days for physical activity [5,6] or two weeks when measuring blood glucose [7,8], or even multiple months when monitoring behavior change [9].”
BackgroundOganesova, Z., Pembérton, J. H., & Brown, A. C. (2024) · Diabetic Medicine · doi:10.1111/dme.15369 · Cited by 31
“1 CGMs could reveal these interactions by graphically associating and visualising lifestyle factors with corresponding high or low glucose results, thus potentially fostering healthier lifestyle practices, as observed in people living with prediabetes, T1DM, and T2DM.”
InfluentialMulti-Horizon Glucose Prediction Across Populations With Deep Domain Generalization
Zhu, T., Afentakis, I., Li, K., Armiger, R., Hill, N. E., Oliver, N. S., & Georgiou, P. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3428921 · Cited by 26
“Consequently, CGM has been endorsed as a standard element of T1D management [6], [7].”
Dietary Patterns of Insulin Pump and Multiple Daily Injection Users During Type 1 Diabetes Pregnancy
Neoh, S. L., Yamamoto, J. M., Feig, D. S., Murphy, H. R., CONCEPTT Collaborative Group, Murphy, H. R., Grisoni, J., Byrne, C., Neoh, S., Davenport, K., et al. (2019) · Diabetes Care · doi:10.2337/dc19-1908 · Cited by 18
“premeal boluses and increased focus on the CGM targets during this period of increasing insulin resistance, aiming for 70% CGM TIR 63–140 mg/dL in midpregnancy (5), may help insulin pump users achieve better glycemic and neonatal outcomes.”
BackgroundSelf-citationPréau, Y., Armand, M., Galie, S., Schaepelynck, P., & Raccah, D. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0515 · Cited by 20
Glycemic Status Assessment by the Latest Glucose Monitoring Technologies
Malandrucco, I., Russo, B., Picconi, F., Menduni, M., & Frontoni, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218243 · Cited by 17
“Establishing target percentages of time in the various glycemic ranges with the ability to adjust the percentage cut points to address the specific needs of special diabetes populations (pregnancy, high-risk) facilitates safe and effective therapeutic decision making within the parameters of the established glycemic g…”
BackgroundInfluentialBahillo-Curieses, P., Díaz-Soto, G., Martínez, A. M. V., Ballester, I. T., Hoyos, E. G., & Román, D. A. D. L. (2021) · Endocrine · doi:10.1007/s12020-021-02691-4 · Cited by 21
Calcaterra, V., Bosoni, P., Dilillo, D., Mannarino, S., Fiori, L., Fabiano, V., Carlucci, P., Profio, E. D., Verduci, E., Mameli, C., et al. (2021) · Children · doi:10.3390/children8050384 · Cited by 21
“The isCGM data were investigated through the computation of the most useful metrics in clinical practice according to the Advanced Technologies and Treatments for Diabetes (ATTD) consensus recommendations [27], such as: • Average glucose; • Glucose standard deviation (SD); • Time below range (TBR), i.”
MethodHorowitz, M., Kaye, W. A., Pepper, G. M., Reynolds, K. E., Patel, S., Knudson, K. C., Kale, G. K., Gutiérrez, M. E. H., Cotto, L., & Horowitz, B. S. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108876 · Cited by 17
Glucose Patterns in Very Old Adults: A Pilot Study in a Community-Based Population
Selvin, E., Wang, D., Tang, O., Minotti, M., Echouffo-Tcheugui, J. B., & Coresh, J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0156 · Cited by 21
Continuous glucose monitoring in primary care – are we there?
Martens, T. W. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000689 · Cited by 21
“On the basis of International Consensus guidance ([28]), they make a compelling case for use of TIR goals to optimize therapy.”
BackgroundMethodElbalshy, M. M., Styles, S. E., Haszard, J. J., Galland, B. C., Crocket, H. R., Jefferies, C., Wiltshire, E. J., Tomlinson, P. A., de Bock, M. I., & Wheeler, B. J. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13331 · Cited by 20
Boscari, F., Ferretto, S., Cavallin, F., Fadini, G. P., Avogaro, A., & Bruttomesso, D. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01884-1 · Cited by 22
Diabetes mellitus in dialysis and renal transplantation
Ben-David, E., Hull, R., & Banerjee, D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211048663 · Cited by 23
Szmuilowicz, E. D., Barbour, L. A., Brown, F. M., Durnwald, C. P., Feig, D. S., O’Malley, G., Polsky, S., & Aleppo, G. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241239341 · Cited by 23
“6 Recommendations per current expert clinical guidance 3,4 for percentage of time spent within the pregnancy-specific TIR, TAR, and TBR are shown in Table 1 and are widely used in clinical practice.”
Exploring Minimally Invasive Approach to Define Stages of Type 1 Diabetes Remotely
Kontola, H., Alanko, I., Koskenniemi, J. J., Löyttyniemi, E., Itoshima, S., Knip, M., Veijola, R., Toppari, J., & Kero, J. T. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0554 · Cited by 19
Metadata
- Authors
- Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
- Affiliations
- University of Ljubljana (SI)
- Kinderkrankenhaus auf der Bult (DE)
- Park Nicollet Health Services (US)
- King's College London (GB)
- Jaeb Center for Health Research (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- American Diabetes Association (US)
- Close Concerns (United States) (US)
- University of Padua (IT)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Sydney (AU)
- Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
- University of Colorado Denver (US)
- Grunberger Diabetes Institute (US)
- University of Sheffield (GB)
- Science Consulting in Diabetes, Neuss, Germany
- University of Washington (US)
- University of Cambridge (GB)
- Shanghai Jiao Tong University (CN)
- University of Virginia (US)
- Breakthrough T1D (US)
- Joslin Diabetes Center (US)
- Endocrinology Research Center (RU)
- KU Leuven (BE)
- University of East Anglia (GB)
- Schneider Children's Medical Center (IL)
- Steno Diabetes Center Copenhagen (DK)
- CGParkin Communications, Inc., Henderson, NV
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
- Biomedical Informatics Consultants LLC, Potomac, MD
- DiaCare, Ahmedabad, Gujarat, India
- University of Florida (US)
- dQ&A Market Research, Inc., San Francisco, CA
- Nihon University (JP)
- Yale University (US)
- Tel Aviv University (IL)
- Corresponding author
- Battelino, Tadej
- ORCID
- Battelino, Tadej
- Danne, Thomas
- Bergenstal, Richard M.
- Amiel, Stephanie A.
- Beck, Roy
- Biester, Torben
- Bosi, Emanuele
- Buckingham, Bruce A.
- Cefalu, William T.
- Close, Kelly L.
- Cobelli, Claudio
- Dassau, Eyal
- DeVries, J. Hans
- Donaghue, Kim C.
- Doyle, Francis J.
- Garg, Satish
- Grunberger, George
- Heller, Simon
- Heinemann, Lutz
- Hirsch, Irl B.
- Hovorka, Roman
- Jia, Weiping
- Kordonouri, Olga
- Kovatchev, Boris
- Kowalski, Aaron
- Laffel, Lori
- Levine, Brian
- Mayorov, Alexander
- Mathieu, Chantal
- Murphy, Helen R.
- Nimri, Revital
- Nørgaard, Kirsten
- Parkin, Christopher G.
- Renard, Eric
- Rodbard, David
- Saboo, Banshi
- Schatz, Desmond
- Stoner, Keaton
- Urakami, Tatsuiko
- Weinzimer, Stuart A.
- Phillip, Moshe
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1593-1603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973648
- OpenAlex
- W2948261890
- Cited by
- 4,237
- References
- 96
- Citations by year
- 2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
- FWCI
- 215.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Insulet Corporation
- MannKind Corporation
- Dexcom
- OPKO Health
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
- Universiteit van Amsterdam
- KU Leuven
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- Abbott Diabetes Care
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
- MeSH terms
- Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.